According to the findings of a randomized controlled trial, supplementation with Camelina sativa oil (CSO) for 12 weeks triggered substantial changes in anthropometric indices (except neck and hip circumference), adiponectin, atherogenic index, lipid profile (except high-density lipoprotein cholesterol [HDL-c]), and alanine transaminase in nonalcoholic fatty liver disease (NAFLD) patients.

Vali Musazadeh et al. aimed to evaluate the influence of CSO (a great source of antioxidants and omega-3 fatty acids) on metabolic and clinical markers in NAFLD. In this triple-blind trial, 46 NAFLD subjects were randomly segregated into the CSO supplementation group and placebo group for 12 weeks. A loss weight diet was given to both the groups. Assessment of levels of liver enzymes, anthropometric indices, lipid profile, atherogenic index, and adiponectin was done for all the patients at baseline and after the treatment.

In contrast to the placebo group, the CSO group exhibited a substantial difference in the adiponectin concentrations, alanine aminotransferase, atherogenic index, low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), triglyceride, waist-to-hip ratio, waist circumference, body mass index, LDL-c/HDL-c, TC/HDL-c, and weight. In the CSO group, no profound differences were witnessed in the HDL-c, neck circumference, hip circumference, and other liver enzymes compared to the placebo group.

Hence, CSO supplementation elicited profound changes in the metabolic and clinical markers.